Foster & Motley Inc. Invests $579,000 in Henry Schein, Inc. $HSIC

Foster & Motley Inc. purchased a new stake in Henry Schein, Inc. (NASDAQ:HSIC) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 6,938 shares of the company’s stock, valued at approximately $579,000.

Other institutional investors have also modified their holdings of the company. Buckland Partners Management Co LLC bought a new position in Henry Schein in the second quarter worth about $1,036,000. Trust Co. of Vermont acquired a new position in shares of Henry Schein during the second quarter valued at $42,000. Bank of New York Mellon Corp bought a new position in shares of Henry Schein during the second quarter worth about $42,261,000. PFG Investments LLC grew its position in shares of Henry Schein by 19.6% during the second quarter. PFG Investments LLC now owns 3,275 shares of the company’s stock worth $274,000 after acquiring an additional 536 shares during the last quarter. Finally, McElhenny Sheffield Capital Management LLC acquired a new stake in shares of Henry Schein in the 2nd quarter worth about $327,000. Institutional investors own 96.62% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on HSIC. Piper Sandler boosted their price objective on Henry Schein from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. BTIG Research lifted their target price on Henry Schein from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday. Barclays reissued an “overweight” rating and issued a $100.00 price target (up from $86.00) on shares of Henry Schein in a research note on Thursday, August 6th. Barrington Research set a $104.00 price objective on shares of Henry Schein in a research note on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a report on Friday, July 31st. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $92.93.

Henry Schein Trading Up 0.1%

Shares of NASDAQ HSIC opened at $89.29 on Thursday. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $92.18. The business has a fifty day simple moving average of $85.43 and a 200-day simple moving average of $79.36. The company has a market cap of $9.95 billion, a price-to-earnings ratio of 26.03, a P/E/G ratio of 1.70 and a beta of 0.80. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.03. The business had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Sell-side analysts predict that Henry Schein, Inc. will post 5.35 EPS for the current year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.